412 related articles for article (PubMed ID: 28955655)
1. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.
Jhawar SR; Thandoni A; Bommareddy PK; Hassan S; Kohlhapp FJ; Goyal S; Schenkel JM; Silk AW; Zloza A
Front Oncol; 2017; 7():202. PubMed ID: 28955655
[TBL] [Abstract][Full Text] [Related]
2. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
Feola S; Russo S; Ylösmäki E; Cerullo V
Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
[TBL] [Abstract][Full Text] [Related]
4. Application of oncolytic virus in tumor therapy.
Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
[TBL] [Abstract][Full Text] [Related]
5. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic viruses: challenges and considerations in an evolving clinical landscape.
Lauer UM; Beil J
Future Oncol; 2022 Jul; ():. PubMed ID: 35818970
[TBL] [Abstract][Full Text] [Related]
7. Genetic modification of oncolytic viruses to enhance antitumor immunity.
Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
[TBL] [Abstract][Full Text] [Related]
8. Combining oncolytic virus with FDA approved pharmacological agents for cancer therapy.
Zhang W; Chen CC; Ning J
Expert Opin Biol Ther; 2021 Feb; 21(2):183-189. PubMed ID: 32799567
[TBL] [Abstract][Full Text] [Related]
9. Review: Oncolytic virotherapy, updates and future directions.
Fountzilas C; Patel S; Mahalingam D
Oncotarget; 2017 Nov; 8(60):102617-102639. PubMed ID: 29254276
[TBL] [Abstract][Full Text] [Related]
10. From Benchtop to Bedside: A Review of Oncolytic Virotherapy.
Choi AH; O'Leary MP; Fong Y; Chen NG
Biomedicines; 2016 Aug; 4(3):. PubMed ID: 28536385
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Nguyen HM; Guz-Montgomery K; Saha D
Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
[TBL] [Abstract][Full Text] [Related]
12. Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer.
Wang Z; Sun P; Li Z; Xiao S
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958464
[TBL] [Abstract][Full Text] [Related]
13. Viruses as nanomedicine for cancer.
Badrinath N; Heo J; Yoo SY
Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
[TBL] [Abstract][Full Text] [Related]
14. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Holay N; Kim Y; Lee P; Gujar S
Front Immunol; 2017; 8():800. PubMed ID: 28751892
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
16. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen T; Avci NG; Shin DH; Martinez-Velez N; Jiang H
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857493
[TBL] [Abstract][Full Text] [Related]
17. Advances in the clinical development of oncolytic viruses.
Li K; Zhao Y; Hu X; Jiao J; Wang W; Yao H
Am J Transl Res; 2022; 14(6):4192-4206. PubMed ID: 35836877
[TBL] [Abstract][Full Text] [Related]
18. Genetic Modifications That Expand Oncolytic Virus Potency.
Cristi F; Gutiérrez T; Hitt MM; Shmulevitz M
Front Mol Biosci; 2022; 9():831091. PubMed ID: 35155581
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
20. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
